KMT2Ar clinical trials at UCSF
1 research study open to eligible people
KMT2Ar is a genetic mutation related to certain types of leukemia. At UCSF, trials are underway testing ziftomenib paired with regular therapies for patients whose acute myeloid leukemia has come back or is hard to treat. UCSF gathers data on safety and patient experiences during these tests.
Showing trials for
Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
open to eligible people ages 18 years and up
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
San Francisco, California and other locations
Last updated: